Eli Lilly & Co. 2006 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2006. Eli Lilly and Company is a global pharmaceutical firm operating primarily in one significant business segment: pharmaceutical products. The company also maintains an animal health segment, which is not material to consolidated financial statements. Lilly discovers, develops, manufactures, and sells products in approximately 140 countries, with major therapeutic areas including neuroscience, endocrinology (diabetes, osteoporosis), oncology, and cardiovascular health.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Net Sales | $15.69 billion | $14.65 billion |
| Net Income | $2.66 billion | $1.98 billion |
| Earnings Per Share (Diluted) | $2.45 | $1.81 |
| Gross Margin | 77.4% | 76.3% |
| Operating Cash Flow | $3.98 billion | $1.91 billion |
| Total Debt | $3.71 billion | $6.48 billion |
| Cash and Short-term Investments | $3.89 billion | $5.04 billion |
| Effective Tax Rate | 22.1% | 26.3% |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales increased 7% to $15.69 billion, driven by strong growth in Cymbalta (94% increase), Forteo (53% increase), and Alimta (32% increase). U.S. sales rose 10%, while sales outside the U.S. rose 4%.
- Profitability: Net income increased 35% to $2.66 billion. This growth occurred despite significant litigation charges. The gross margin improved to 77.4% due to higher product prices and volume.
- Special Charges: The company recorded $450.3 million in asset impairments and restructuring charges in Q4 2006. Additionally, a $494.9 million pretax charge was recorded for Zyprexa product liability settlements. In 2005, a larger $1.07 billion charge was recorded for similar matters.
- Debt Reduction: Total debt decreased significantly by $2.78 billion during 2006 due to repayments, reducing the total debt load from $6.48 billion to $3.71 billion.
- Acquisitions: In January 2007 (post-period), Lilly acquired ICOS Corporation for approximately $2.3 billion to gain full ownership of Cialis.
Guidance, Outlook, and Risks
- 2007 Guidance: Management expects 2007 earnings per share to range from $2.89 to $2.99. This guidance includes estimated dilutive impacts from the ICOS acquisition and charges for acquired in-process research and development (IPR&D). Sales are expected to grow in the high single or low double digits.
- Key Risks:
- Product Liability: Significant exposure remains regarding Zyprexa litigation, with approximately 1,300 claims remaining after recent settlements. The company is largely self-insured for future product liability losses.
- Patent Expirations: Major products face patent expirations in the coming decade (e.g., Zyprexa in 2011, Cymbalta in 2013, Humalog in 2013), which could lead to generic competition and price erosion.
- Regulatory Environment: Ongoing government investigations into marketing practices (Zyprexa, Prozac) and increasing pressure on pharmaceutical pricing and reimbursement (Medicare Part D, Medicaid rebates).
- R&D Uncertainty: High costs and failure rates inherent in drug development pose risks to future growth.
Investor Verification Checklist
- Zyprexa Litigation Status: Verify the final resolution of the remaining ~1,300 Zyprexa claims and the outcome of the insurance carrier disputes regarding coverage.
- ICOS Integration: Monitor the financial impact of the ICOS acquisition in 2007, specifically the amortization of intangibles and the full consolidation of Cialis revenue.
- Patent Challenges: Track the status of Hatch-Waxman litigation for Zyprexa, Evista, and Gemzar, as unfavorable outcomes could materially impact future revenue.
- Government Investigations: Review updates on the multi-state investigation into Zyprexa marketing practices and the U.S. Attorney's inquiry into rebate agreements.
- Product Pipeline: Assess the progress of late-stage pipeline candidates, particularly in diabetes (e.g., GKA program) and oncology, to ensure future growth drivers.